Geode Capital Management LLC Boosts Stake in Insulet Corporation $PODD

Geode Capital Management LLC grew its stake in shares of Insulet Corporation (NASDAQ:PODD) by 2.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,006,413 shares of the medical instruments supplier’s stock after buying an additional 41,019 shares during the quarter. Geode Capital Management LLC owned 2.85% of Insulet worth $568,274,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Employees Retirement System of Texas raised its position in shares of Insulet by 15.1% during the 4th quarter. Employees Retirement System of Texas now owns 8,342 shares of the medical instruments supplier’s stock valued at $2,371,000 after buying an additional 1,092 shares in the last quarter. Allstate Corp raised its position in shares of Insulet by 110.3% during the 4th quarter. Allstate Corp now owns 5,247 shares of the medical instruments supplier’s stock valued at $1,491,000 after buying an additional 2,752 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC raised its position in shares of Insulet by 1,948.0% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 512 shares of the medical instruments supplier’s stock valued at $146,000 after buying an additional 487 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of Insulet by 14.0% during the 4th quarter. Fisher Asset Management LLC now owns 52,735 shares of the medical instruments supplier’s stock valued at $14,989,000 after buying an additional 6,462 shares in the last quarter. Finally, Clearstead Advisors LLC raised its position in shares of Insulet by 200.4% during the 4th quarter. Clearstead Advisors LLC now owns 745 shares of the medical instruments supplier’s stock valued at $212,000 after buying an additional 497 shares in the last quarter.

Wall Street Analyst Weigh In

PODD has been the topic of several research reports. Benchmark restated a “buy” rating on shares of Insulet in a research report on Wednesday. Citigroup lowered their price objective on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday. Raymond James Financial lowered their price objective on shares of Insulet from $355.00 to $263.00 in a research report on Thursday, May 7th. Canaccord Genuity Group reduced their target price on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Piper Sandler reduced their target price on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average target price of $252.04.

Insulet Price Performance

PODD stock opened at $144.94 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 52 week low of $140.63 and a 52 week high of $354.88. The firm’s fifty day moving average is $183.55 and its 200 day moving average is $245.30. The firm has a market cap of $10.04 billion, a P/E ratio of 33.71, a P/E/G ratio of 1.15 and a beta of 1.20.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the firm earned $1.02 EPS. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts predict that Insulet Corporation will post 6.44 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.